ACW receives further $1.9m FY2025 R&D rebate from ATO
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Actinogen Medical Limited has announced the receipt of a research and development tax incentive rebate from the Australian Tax Office related to the financial year. The rebate amounts to a significant sum and is part of the company's funding strategy as it progresses in its Alzheimer's clinical trial. This announcement highlights the importance of the RDTI program for the company's ongoing operations and future milestones.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
- ACW secures funding beyond XanaMIA AD trial final results
- ACW December 2025 quarterly activity report & Appendix 4C
- Continuation of Trading Halt
- ACW positive XanaMIA Interim Analysis outcome
Later from Actinogen Medical
- Actinogen HY2025 financial report and Appendix 4D
- ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
- ACW successfully completes $16.8m Placement and SPP
- ACW XanaMIA Alzheimers open label trial commences
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical